EDAP ExactVu ultrasound biopsy system gets approval in Japan

Apr. 06, 2023 8:22 AM ETEDAP TMS S.A. (EDAP)By: Ravikash, SA News Editor

EDAP TMS (NASDAQ:EDAP) said Japan's Pharmaceutical and Medical Devices Agency (PMDA) approved its ExactVu micro-ultrasound biopsy platform.
The French company added that the approval allows for market launch of the only micro-ultrasound platform for precision prostate biopsies.
EDAP noted that the unique 29MHz frequency allows practitioners to visualize details unseen before in any prostate ultrasound image and detect suspicious areas in real-time.
The device is already available for sale in the U.S. and the EU.
"Our established commercial team in Japan is well positioned to engage clinical sites to offer their patients precise prostate biopsies utilizing this groundbreaking technology," said EDAP Chairman and CEO Marc Oczachowski.